FI108777B - Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft - Google Patents

Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft Download PDF

Info

Publication number
FI108777B
FI108777B FI913926A FI913926A FI108777B FI 108777 B FI108777 B FI 108777B FI 913926 A FI913926 A FI 913926A FI 913926 A FI913926 A FI 913926A FI 108777 B FI108777 B FI 108777B
Authority
FI
Finland
Prior art keywords
cdr
groups
antibody
positions
light chain
Prior art date
Application number
FI913926A
Other languages
English (en)
Finnish (fi)
Other versions
FI913926A0 (fi
Inventor
John Spencer Emtage
John Robert Adair
Diljeet Singh Athwal
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI108777(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of FI913926A0 publication Critical patent/FI913926A0/fi
Application granted granted Critical
Publication of FI108777B publication Critical patent/FI108777B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (16)

1. Förfarande för att producera en antikroppsmolekyl be-arbetad med CDR-graft, kännetecknat av att det innefattar att 20 (a) i expressionsvektorn bilda en operon med en DNA- .·. sekvens som kodar den tunga kedjan i den med CDR-graft be- arbetade antikroppen, med ett varierande strukturomräde innefattande acceptorns framework-omräde och donorns anti-/ gen bindande omräden, och där framework-omrädet innefattar : ·* 25 donorgrupper ätminstone i en av positionerna 6, 23, * * och/eller 24, 28 och/eller 49, 71 och/eller 73, 75 v · och/eller 76 och/eller 78 och 88 och/eller 91, och/eller (b) i expressionsvektorn bilda en operon med en DNA-sek-·:··: vens som kodar den komplementära Iät ta kedjan i den med ·"*: 30 CDR-graft bearbetade antikroppen, med ett varierande ' . strukturomräde innefattande acceptorns framework-omrade ' och donorns antigen bindande omräden, och där framework- | omrädet innefattar donorgrupper ätminstone i en av posi- tionerna (i) 1 och/eller 3 och 46 och/eller 47 och/eller ;···; 35 (ii) 46, 48, 58 och 71; 76 1 0 8 7 7 7 (c) transfektera värdcellen med en vektor eller varje vek-tor, och (d) odla den transfekterade cellinjen för att producera en antikroppsmolekyl innehällande ett CDR-graft. 5
2. Förfarande enligt patentkrav 1, kännetecknat av att operonen som kodar den tunga kedjan kodar den med CDR-graft bearbetade tunga kedjan innefattande ett varierande strukturomräde, i vars framework-omräde finns donorgrupper i positioner 23, 24, 49, 71, 73 och 78 eller positionerna 10 23, 24 och 49.
3. Förfarande enligt patentkrav 2, kännetecknat av att i framework-omrädet finns donorgrupper i positioner 2, 4, 6, 25, 36, 37, 39, 47, 48, 93, 94, 103, 104, 106 och 107.
4. Förfarande enligt patentkrav 2 eller 3, kännetecknat 15 av att i framework-omrädet finns donorgrupper i ett, nägra eller varje av positionerna: 1 och 3, 69 (ifall 48 är olika i donorn och acceptorn), 36 och 46 (ifall 48 är en donorgrupp), .·. 20 67, • · · 82 och 18 (ifall 67 är en donorgrupp) , 9i och vilken som heist av en eller flera positioner 9, 11, 41, ·' 87, 108, 110 och 112. v : 25
5. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att operonen som kodar den tunga kedjan *:··: kodar en tung kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde i vars framework-omräde • . finns donor-CDR i positioner 26-35, 50-65 och 95-100. • · 30
6. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att operonen som kodar den lätta kedjan kodar en lätt kedja bearbetad med CDR-graft innefattande 108777 77 ett varierande strukturomräde i vars framework-omräde finns donorgrupper i positioner 46 och 47.
7. Förfarande enligt nägot av föregäende patentkrav, kannetecknat av att operonen som kodar den Iätta kedjan 5 kodar en lätt kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde i vars framework-omräde finns donorgrupper i positioner 46, 48, 58 och 71.
8. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att operonen som kodar den Iätta kedjan 10 kodar en lätt kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde i vars framework-omräde f inns donorgrupper i positioner 2, 4, 6, 35, 36, 38, 44, 47, 49, 62, 64-69, 85, 87, 98, 99, 101 och 102. I
9. Förfarande enligt patentkrav 1 eller 8, kännetecknat 15 av att operonen som kodar den lätta kedjan kodar en lätt kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde i vars framework-omräde finns donorgrupper i en, nägra eller varje av följande positioner 1 och 3, 20 63, • · · . 60 (ifall 60 och 54 förmär bilda en potentiell saltbrygga) 70 (ifall 70 och 24 förmär bilda en potentiell saltbrygga) 73 och 21 (ifall 47 är olika i donorn och acceptorn) ·' ·' 37 och 45 (ifall 47 är olika i donorn och acceptorn) 25 och v ; i vilken som heist en eller flera av positioner 10, 12, 40, 83, 103 OCh 105. » ·
10. Förfarande enligt nägot av föregäende patentkrav, ’ . kännetecknat av att operonen som kodar den lätta kedjan ‘ 30 kodar en lätt kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde i vars framework-omräde finns donor-CDR i positionerna 24-34, 50-56 och 89-97. • · · 78 1 08 777
11. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att den med CDR-graft bearbetade anti-kroppsmolekylen är en platsspecifik antikroppsmolekyl.
12. Förfarande enligt nägot av föregäende patentkrav, 5 kannetecknat av att den med CDR-graft bearbetade anti- kroppsmolekylen har specificitet mot interleukin, hormon eller nägon annan biologiskt aktiv förening eller dess receptor.
13. Förfarande enligt nägot av föregäende patentkrav, 10 kännetecknat av att operonen som kodar den tunga kedjan ' eller den lätta kedjan kodar en tung kedja eller en lätt kedja bearbetad med CDR-graft innefattande ett varierande strukturomräde med acceptorgrupper av human typ och donor-grupper av icke-human typ.
14. DNA-sekvens innefattande en kodningssekvens för en operon av en tung kedja eller en lätt kedja enligt nägot av föregäende patentkrav.
15. Klonings- eller expressionsvektor innefattande en .·. DNA-sekvens enligt patentkrav 14. • · · 20
16. Värdcell som transformerats med en DNA-sekvens enligt patentkrav 14 eller en klonings- eller expressionsvektor • · · 1 ·' ·* enligt patentkrav 15. * · ! * * · i ♦ » » · · * ) *
FI913926A 1989-12-21 1991-08-20 Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft FI108777B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8928874 1989-12-21
GB898928874A GB8928874D0 (en) 1989-12-21 1989-12-21 Humanised antibodies
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GB9002017 1990-12-21

Publications (2)

Publication Number Publication Date
FI913926A0 FI913926A0 (fi) 1991-08-20
FI108777B true FI108777B (sv) 2002-03-28

Family

ID=10668300

Family Applications (4)

Application Number Title Priority Date Filing Date
FI913932A FI108917B (sv) 1989-12-21 1991-08-20 Förfarande för framställning av en terapeutiskt användbar CD4-specifik rekombinantantikropp
FI913926A FI108777B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft
FI913927A FI108776B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antantikroppsmolekyl bearbetad med anti-CD3-CDR-graft
FI990875A FI109768B (sv) 1989-12-21 1999-04-19 CD4-specifik rekombinantantikropp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI913932A FI108917B (sv) 1989-12-21 1991-08-20 Förfarande för framställning av en terapeutiskt användbar CD4-specifik rekombinantantikropp

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI913927A FI108776B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antantikroppsmolekyl bearbetad med anti-CD3-CDR-graft
FI990875A FI109768B (sv) 1989-12-21 1999-04-19 CD4-specifik rekombinantantikropp

Country Status (21)

Country Link
US (10) US5929212A (sv)
EP (5) EP0626390B1 (sv)
JP (4) JP3242913B2 (sv)
KR (3) KR100197956B1 (sv)
AT (4) ATE129017T1 (sv)
AU (4) AU631481B2 (sv)
BG (1) BG60462B1 (sv)
BR (1) BR9007197A (sv)
CA (3) CA2046904C (sv)
DE (4) DE69033857T2 (sv)
DK (4) DK0460178T3 (sv)
ES (4) ES2074701T3 (sv)
FI (4) FI108917B (sv)
GB (4) GB8928874D0 (sv)
GR (2) GR3017734T3 (sv)
HU (4) HU215383B (sv)
NO (5) NO913229L (sv)
RO (3) RO114980B1 (sv)
RU (1) RU2112037C1 (sv)
WO (3) WO1991009966A1 (sv)
ZA (1) ZA9110129B (sv)

Families Citing this family (1331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
DE69126301T2 (de) * 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9104498D0 (en) * 1991-03-04 1991-04-17 Ks Biomedix Ltd Antibody
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1993012220A1 (en) * 1991-12-12 1993-06-24 Berlex Laboratories, Inc. RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) * 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
CA2176237A1 (en) * 1993-11-10 1995-05-18 Richard P. Darveau Treatment of bacterially-induced inflammatory diseases
AU7949394A (en) 1993-11-19 1995-06-06 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
EP0749488A1 (en) * 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JPH09512705A (ja) 1994-03-29 1997-12-22 セルテック セラピューティクス リミテッド Ｅ−セレクチンに対する抗体
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1996020281A1 (en) * 1994-12-23 1996-07-04 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
JPH10511846A (ja) * 1994-12-28 1998-11-17 ユニバーシティ オブ ケンタッキー ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体３ｈ１配列
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
DE69627665T2 (de) * 1995-05-18 2004-02-19 Ortho-Mcneil Pharmaceutical, Inc. Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern
ATE266726T1 (de) 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP2258726A1 (en) * 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1378525A3 (en) 1996-06-07 2004-01-14 Neorx Corporation Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
CA2644454A1 (en) * 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
BRPI9809388B8 (pt) * 1997-04-07 2021-05-25 Genentech Inc anticorpos humanizados e métodos para a formação de anticorpos humanizados.
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
ES2293691T3 (es) 1997-10-03 2008-03-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humano natural.
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2002506625A (ja) 1998-03-19 2002-03-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド サイトカインレセプター共通γ鎖様
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
CZ302070B6 (cs) * 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
EP1117808B1 (en) 1998-10-06 2004-12-29 Mark Aaron Emalfarb Transformation system in the field of filamentous fungal hosts: in chrysosporium
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BRPI9915679B8 (pt) 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU782115B2 (en) * 1999-09-22 2005-07-07 Ortho-Mcneil Pharmaceutical, Inc. Cell based assay
DE60038252T2 (de) * 1999-09-30 2009-03-19 Kyowa Hakko Kogyo Co., Ltd. Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
EP1783227A1 (en) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
MXPA02007449A (es) * 2000-02-03 2003-04-14 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
WO2001062801A2 (en) 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
EP1418234A4 (en) * 2000-03-02 2005-03-16 Abgenix Inc HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST OXIDIZED LDL RECEPTORS AND THEIR MEDICAL USE
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ１８抗体と抗ｃｃｒ２抗体の混合物を用いる狭窄および再狭窄を抑制する方法
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1881004B1 (en) 2000-04-21 2012-07-25 Fuso Pharmaceutical Industries, Ltd. Novel collectin
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
WO2002030986A2 (en) 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2412384A1 (en) 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Abgenix Inc anticorpos para receptor de fator de crescimento i semelhante à insulina
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP4729717B2 (ja) * 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
KR101027889B1 (ko) * 2001-10-15 2011-04-07 아이비씨 파마슈티컬스, 인코퍼레이티드 친화력 증강제
CA2463927A1 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
CA2467633C (en) * 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
CA2478547C (en) * 2001-12-03 2011-09-20 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
WO2003048729A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP1534752B1 (en) 2002-05-01 2011-08-03 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
EP2070949B1 (en) 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003243651B2 (en) 2002-06-17 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003248782A1 (en) 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP2371859A3 (en) * 2002-07-19 2011-12-28 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
US8071321B2 (en) 2002-08-29 2011-12-06 Cytocure Llc Methods for up-regulating antigen expression in tumors
JP4790413B2 (ja) 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004039845A1 (en) * 2002-10-31 2004-05-13 Universita'degli Studi Di Roma 'la Sapienza' Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
WO2004043239A2 (en) * 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
ATE481422T1 (de) 2002-11-21 2010-10-15 Celltech R & D Inc Modulieren von immunantworten
NZ540562A (en) 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
WO2004058171A2 (en) 2002-12-20 2004-07-15 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
EP1596809B1 (en) * 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Abeta binding molecules
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
CA2823468A1 (en) 2003-04-23 2004-11-04 Medarex, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
RS20050934A (en) 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
WO2005010040A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
DE602004031239D1 (de) * 2003-07-21 2011-03-10 Immunogen Inc Verfahren zu dessen anwendung
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
JP4638870B2 (ja) 2003-08-13 2011-02-23 ファイザー・プロダクツ・インク 修飾ヒトｉｇｆ−１ｒ抗体
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン，エルエルシー 抗体のヒト化
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
AU2004283850C1 (en) * 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
CN1871359B (zh) 2003-10-22 2010-11-17 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
WO2005054868A1 (en) * 2003-12-05 2005-06-16 Multimmune Gmbh Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
HUE064610T2 (hu) 2003-12-23 2024-04-28 Genentech Inc Új anti-IL 13 antitestek és alkalmazásaik
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
WO2005068504A1 (ja) 2004-01-19 2005-07-28 Medical And Biological Laboratories Co., Ltd. 炎症性サイトカイン抑制剤
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
PL1781705T3 (pl) 2004-06-21 2015-03-31 Squibb & Sons Llc Antyciała receptora interferonów alfa I oraz ich zastosowania
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
JP5014130B2 (ja) * 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
AU2005313026B2 (en) 2004-12-06 2011-09-08 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
JP5265923B2 (ja) 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド 軽度の変形性関節症のバイオマーカーおよびその使用
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
US8211430B2 (en) 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
RS59399B1 (sr) 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
MX2007013609A (es) 2005-05-06 2008-01-24 Zymogenetics Inc Anticuerpos monoclonales de il-31 y meodos de uso.
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
CN103146708A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
EP1904652A2 (en) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP2311876A3 (en) 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500356A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2624135C (en) 2005-09-29 2015-06-30 Eisai R & D Management Co., Ltd. T-cell adhesion molecule and antibody thereto
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
ATE518007T1 (de) 2005-10-21 2011-08-15 Genenews Inc Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
JP2009517340A (ja) 2005-11-04 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
WO2007064882A2 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
BRPI0619595B8 (pt) 2005-12-09 2022-12-13 Ucb Pharma Sa anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
WO2007071426A1 (en) 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical compositions with resistance to soluble cea
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
AU2007207341B2 (en) 2006-01-20 2012-05-10 Women's & Children's Health Research Institute Incorporated Method of treatment, prophylaxis and diagnosis of pathologies of the bone
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PL1994055T3 (pl) 2006-03-10 2015-02-27 Wyeth Llc Przeciwciała anty-5T4 i ich zastosowanie
CN103641916A (zh) 2006-03-27 2014-03-19 医学免疫有限公司 Gm-csf受体结合元件
KR20150006085A (ko) 2006-04-05 2015-01-15 애브비 바이오테크놀로지 리미티드 항체 정제
CA2648582C (en) 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
ES2599319T3 (es) * 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
CN101484199B (zh) 2006-06-30 2014-06-25 艾伯维生物技术有限公司 自动注射装置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
BRPI0712953B8 (pt) 2006-06-30 2021-05-25 Novo Nordisk As anticorpos anti-nkg2a, seu uso, e composição farmacêutica
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
KR101193722B1 (ko) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
PT2594586E (pt) 2006-09-01 2014-11-26 Zymogenetics Inc Anticorpos monoclonais de il-31 e métodos de utilização
US7915388B2 (en) 2006-09-08 2011-03-29 Abbott Laboratories Interleukin-13 binding proteins
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP5279504B2 (ja) 2006-11-17 2013-09-04 一般財団法人阪大微生物病研究会 神経伸長促進剤および伸長阻害剤
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
EP2101813B1 (en) 2006-11-27 2014-04-02 Patrys Limited Novel glycosylated peptide target in neoplastic cells
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
EA200900767A1 (ru) 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
KR20150004933A (ko) 2006-12-18 2015-01-13 제넨테크, 인크. 항-ｎｏｔｃｈ3 길항제 항체 및 ｎｏｔｃｈ3-관련 질환의 예방 및 치료에 있어서 그의 용도
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
ES2673153T3 (es) 2007-01-09 2018-06-20 Biogen Ma Inc. Anticuerpos Sp35 y usos de los mismos
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP5867795B2 (ja) 2007-02-01 2016-02-24 テーツェーエフ ゲゼルシャフト ミット ベシュレンクテル ハフツング 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
JP5721951B2 (ja) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2164868B1 (en) 2007-05-04 2015-03-25 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Engineered rabbit antibody variable domains and uses thereof
SI3072525T1 (en) 2007-05-14 2018-06-29 Astrazeneca Ab Procedures for lowering the levels of basophiles
US8318163B2 (en) 2007-05-17 2012-11-27 Genentech, Inc. Anti-pan neuropilin antibody and binding fragments thereof
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
LT2164514T (lt) 2007-05-21 2017-03-10 Alderbio Holdings Llc Il-6 antikūnai ir jų naudojimas
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
WO2008144757A1 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
GB0712503D0 (en) * 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
MX346172B (es) 2007-08-29 2017-03-10 Sanofi - Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
KR20100080519A (ko) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
CN101951948B (zh) * 2007-08-31 2015-12-09 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
JP2010539243A (ja) 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
CA3102704A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
DK2238168T3 (da) 2007-12-26 2014-08-25 Biotest Ag Midler, der er målrettet mod cd138 og anvendelser deraf
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
MX2010007101A (es) 2007-12-26 2011-07-01 Biotest Ag Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138.
PT2242772E (pt) 2007-12-26 2015-02-09 Biotest Ag Imunoconjugados dirigidos contra cd138 e as suas utilizações
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
WO2009088105A1 (en) 2008-01-11 2009-07-16 Gene Techno Science Co., Ltd. HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
EP2244729B1 (en) 2008-01-18 2016-11-02 MedImmune, LLC Cysteine engineered antibodies for site-specific conjugation
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20100135808A (ko) 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
AU2009235622C9 (en) 2008-03-13 2015-07-02 Biotest Ag Agent for treating disease
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US20110028697A1 (en) 2008-03-27 2011-02-03 Takara Bio Inc. Prophylactic/therapeutic agent for infectious disease
EP2281005B1 (en) 2008-04-03 2013-11-20 Vib Vzw Single domain antibodies capable of modulating bace1 activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN104530233B (zh) 2008-04-24 2018-01-30 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2500361B1 (en) 2008-05-09 2016-03-30 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2297186B1 (en) 2008-05-29 2018-08-29 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Expression and assembly of human group c rotavirus-like particles and uses thereof
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
PT2307457T (pt) 2008-06-25 2018-10-16 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o tnf
KR102007492B1 (ko) * 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
SG192496A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 binding proteins and uses thereof
EP2321422A4 (en) 2008-07-08 2013-06-19 Abbvie Inc PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
JP5692746B2 (ja) 2008-08-07 2015-04-01 国立大学法人 長崎大学 全身性疼痛症候群の治療または予防薬
EP2324060B1 (en) 2008-09-07 2015-07-22 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
PT2356153T (pt) 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
US8481033B2 (en) 2008-10-07 2013-07-09 INSERM (Institute National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
BRPI0918122A8 (pt) 2008-12-19 2017-01-24 Macrogenics Inc molécula de diabody, diabody, e mólecula dart
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
JP2012516153A (ja) 2009-01-29 2012-07-19 アボット・ラボラトリーズ Ｉｌ−１結合タンパク質
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
UY32451A (es) 2009-02-17 2010-09-30 Ucb Pharma Sa Moléculas de anticuerpo con especifidad por el ox40 humano
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
EP2406285B1 (en) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EA024695B1 (ru) * 2009-03-16 2016-10-31 Сефалон Острэйлиа Пти Лтд. Гуманизированные антитела с противоопухолевой активностью
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
EP2412825B8 (en) 2009-03-24 2018-01-10 Riken Leukemia stem cell markers
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
CN104558179A (zh) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 用于治疗血液肿瘤的抗IL-3Rα抗体
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
LT2438087T (lt) 2009-06-05 2017-08-25 Ablynx N.V. Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
EP2440934B1 (en) 2009-06-08 2014-07-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8956614B2 (en) 2009-06-15 2015-02-17 Vib Vzw BACE1 inhibitory antibodies
ES2534355T3 (es) 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anticuerpos anti-VEGF y sus usos
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
NZ597458A (en) 2009-07-03 2014-01-31 Bionor Immuno As Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN102741288B (zh) 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
AU2010286427A1 (en) 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
MX351635B (es) 2009-10-16 2017-10-23 Servier Lab Anticuerpos monoclonales frente a progastrina y sus usos.
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2639056T3 (es) 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
BR112012011463A2 (pt) 2009-10-30 2017-05-02 Abbott Biotherapeutics Corp uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2506869A1 (en) 2009-12-04 2012-10-10 VIB vzw Arf6 as a new target for treating alzheimer's disease
ES2562832T3 (es) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
EP2516463B1 (en) 2009-12-23 2016-06-15 4-Antibody AG Binding members for human cytomegalovirus
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
JP5964249B2 (ja) 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド 治療用ｄｌｌ４結合タンパク質
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US20150071912A1 (en) 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US8986689B2 (en) 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
PL2558499T3 (pl) 2010-04-16 2017-10-31 Biogen Ma Inc Przeciwciała anty-VLA-4
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
US20130143797A1 (en) 2010-06-25 2013-06-06 Michael J. Tisdale Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
PL2598531T3 (pl) 2010-07-26 2021-08-30 Progastrine Et Cancers S.À R.L. Sposoby i kompozycje do terapii nowotworu wątroby
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
ES2664989T3 (es) 2010-10-01 2018-04-24 National Research Council Of Canada Anticuerpos ANTI-CEACAM6 y usos de los mismos
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
EP3708586A1 (en) 2010-10-29 2020-09-16 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd NEUTRALIZATION OF ANTIBODIES TO CCL20
DK2643018T3 (da) 2010-11-23 2021-01-18 Vitaeris Inc Anti-il-6-antistoffer til behandling af oral mucositis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
BR112013015944A2 (pt) 2010-12-21 2018-06-19 Abbvie Inc imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
ES2684602T3 (es) 2010-12-22 2018-10-03 Orega Biotech Anticuerpos contra CD39 humano y uso de los mismos
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
CA2823812C (en) 2011-01-14 2017-02-14 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
EP2691419B1 (en) 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
WO2012145714A2 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2704742B1 (en) 2011-05-02 2017-07-12 Millennium Pharmaceuticals, Inc. Formulation for anti- 4 7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2710040B1 (en) 2011-05-19 2017-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
SG195073A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
RU2661677C2 (ru) 2011-05-27 2018-07-18 Аблинкс Нв Ингибирование резорбции кости с помощью связывающих rank-l пептидов
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
WO2012170807A2 (en) 2011-06-10 2012-12-13 Medimmune, Llc Anti-pseudomonas psl binding molecules and uses thereof
JP6120833B2 (ja) 2011-06-22 2017-04-26 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
SI2758432T1 (sl) 2011-09-16 2019-07-31 Ucb Biopharma Sprl Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
US9599608B2 (en) 2011-09-21 2017-03-21 Fujirebio Inc. Antibody against affinity complex
CN103958542A (zh) 2011-09-23 2014-07-30 抗菌技术,生物技术研究与发展股份有限公司 经修饰的白蛋白结合结构域及其用于改善药代动力学的用途
RU2014117510A (ru) 2011-10-10 2015-11-20 Медиммьюн Лимитед Лечение ревматоидного артрита
MX2014004977A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes dirigidos contra esclerostina.
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2599496A1 (en) 2011-11-30 2013-06-05 Kenta Biotech AG Novel targets of Acinetobacter baumannii
TWI640537B (zh) 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
ES2684950T3 (es) 2011-12-08 2018-10-05 Biotest Ag Usos de inmunoconjugados dirigidos a CD138
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
EP2793949B1 (en) 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
HUE041900T2 (hu) 2012-01-20 2019-06-28 Genzyme Corp Anti-CXCR3 ellenanyagok
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
CN107880124B (zh) 2012-01-27 2021-08-13 艾伯维德国有限责任两合公司 用于诊断和治疗与神经突变性相关的疾病的组合物和方法
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
PL2814842T3 (pl) 2012-02-15 2018-12-31 Novo Nordisk A/S Przeciwciała wiążące białko 1 rozpoznające peptydoglikan
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3196214B1 (en) 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PT2831113T (pt) 2012-03-28 2018-06-20 Sanofi Sa Anticorpos para ligandos do recetor b1 da bradicinina
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
ES2719495T3 (es) * 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
EP3967323A3 (en) 2012-06-06 2022-05-04 Bionor Immuno AS Hiv vaccine
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
ES2786263T3 (es) 2012-07-13 2020-10-09 Univ Pennsylvania Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
NO2760138T3 (sv) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
DK2906597T3 (da) 2012-10-15 2020-07-13 Medimmune Ltd Antistoffer mod beta-amyloid
CA2889398C (en) 2012-10-24 2023-08-01 National Research Council Of Canada Anti-campylobacter jejuni antibodies and uses therefor
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
PL2922875T3 (pl) 2012-11-20 2017-08-31 Sanofi Przeciwciała anty-CEACAM5 i ich zastosowanie
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US20150322152A1 (en) 2012-11-30 2015-11-12 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
EP2934575A2 (en) 2012-12-19 2015-10-28 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
EA201591219A1 (ru) 2012-12-27 2015-12-30 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
AU2013375015A1 (en) 2013-01-28 2015-08-13 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
SG10201707464SA (en) 2013-03-13 2017-10-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
JP6505076B2 (ja) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
MX2015012825A (es) 2013-03-14 2016-06-10 Abbott Lab Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
JP2016512241A (ja) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP2016514690A (ja) 2013-03-15 2016-05-23 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
CN105377892A (zh) 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
KR20160129698A (ko) 2013-05-24 2016-11-09 메디뮨 엘엘씨 항-b7-h5 항체 및 이의 용도
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
US11161906B2 (en) 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
UA118267C2 (uk) 2013-08-13 2018-12-26 Санофі Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR20160068742A (ko) 2013-09-04 2016-06-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Dpp-4를 표적으로 하는 당뇨병 치료용 백신
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CN104418947A (zh) 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
RU2671089C2 (ru) * 2013-09-16 2018-10-29 Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
PL3021859T3 (pl) 2013-10-25 2018-06-29 Psioxus Therapeutics Limited Adenowirusy onkolityczne wyposażone w geny heterolityczne
AU2014342528A1 (en) 2013-10-28 2016-04-28 Dots Technology Corp. Allergen detection
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
CN106029874B (zh) 2013-12-16 2020-09-15 北卡罗来纳-查佩尔山大学 浆细胞样树突状细胞的耗竭
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
ES2778498T3 (es) 2013-12-20 2020-08-10 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3088000A4 (en) 2013-12-27 2017-08-09 Osaka University Vaccine targeting il-17a
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3114141T3 (da) 2014-03-06 2020-08-10 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
PE20161245A1 (es) 2014-03-06 2016-11-25 Nat Res Council Canada Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
MX2016011560A (es) 2014-03-06 2017-04-13 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3119812B1 (en) 2014-03-21 2020-04-29 X-Body, Inc. Bi-specific antigen-binding polypeptides
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
HRP20240874T1 (hr) 2014-04-07 2024-10-11 Novartis Ag Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3131929B1 (en) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
WO2015168019A2 (en) 2014-04-30 2015-11-05 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
KR102433464B1 (ko) 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
WO2015187428A1 (en) 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
RS65136B1 (sr) 2014-07-17 2024-02-29 Novo Nordisk As Mutageza usmerena na lokaciju trem-1 antitela za smanjenje viskoziteta
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EA034081B1 (ru) 2014-07-29 2019-12-25 Селлектис Ror1-(ntrkr1)-специфические химерные антигенные рецепторы для иммунотерапии рака
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
EP3699188A1 (en) 2014-09-04 2020-08-26 Cellectis 5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
WO2016036937A1 (en) 2014-09-05 2016-03-10 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
CA3001724A1 (en) 2014-10-10 2016-04-14 National Research Council Of Canada Anti-tau antibody and uses thereof
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
CN114836385A (zh) 2014-10-31 2022-08-02 宾夕法尼亚大学董事会 改变cart细胞中的基因表达及其用途
ES2832711T3 (es) 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2015344769B2 (en) 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
DK3218005T5 (da) 2014-11-12 2024-10-14 Seagen Inc Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
EP3227341A1 (en) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3546567A1 (en) 2014-12-06 2019-10-02 GEMoaB Monoclonals GmbH Genetic modified pluri- or multipotent stem cells and uses thereof
WO2016094509A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
MX2017007641A (es) 2014-12-09 2017-10-02 Abbvie Inc Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
WO2016094602A1 (en) 2014-12-10 2016-06-16 Tufts University Vhh based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10793642B2 (en) 2014-12-11 2020-10-06 Inbiomotion S.L. Binding members for human c-MAF
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3233897B1 (en) 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
CN107406509B (zh) * 2014-12-19 2021-10-29 凯奥目生物科学株式会社 包含结合至5t4和cd3的三个结合结构域的融合蛋白
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
GB2557389B (en) 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2017009181A (es) 2015-01-26 2017-11-22 Cellectis Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
WO2016122738A1 (en) 2015-01-31 2016-08-04 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3271388A1 (en) 2015-02-09 2018-01-24 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies specific to glycoprotein (gp) of ebola virus and uses for the treatment and diagnosis of ebola virus infection
BR112017015880A2 (pt) 2015-03-03 2018-07-31 Kymab Ltd anticorpos, usos e métodos
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
WO2016149096A1 (en) 2015-03-13 2016-09-22 President And Fellows Of Harvard College Determination of cells using amplification
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
RU2752918C2 (ru) 2015-04-08 2021-08-11 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
IL287291B (en) 2015-04-28 2022-09-01 Univ Osaka A protein that binds to rgma and its use
EA201792388A1 (ru) 2015-04-30 2018-06-29 Президент Энд Феллоуз Оф Гарвард Колледж Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний
US20180140694A1 (en) 2015-05-04 2018-05-24 Bionor Immuno As Dosage regimen for hiv vaccine
EP3291836A4 (en) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
HRP20231392T1 (hr) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
MA47395A (fr) 2015-05-27 2019-12-11 Ucb Biopharma Sprl Méthode pour le traitement d'une maladie neurologique
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
JP6619460B2 (ja) 2015-06-24 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒト化抗タウ（ｐＳ４２２）抗体及び使用法
PE20180499A1 (es) 2015-07-06 2018-03-09 Ucb Biopharma Sprl Anticuerpos de union a tau
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
EP3319990A1 (en) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies having specificity to myosin 18a and uses thereof
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
EP3334442A1 (en) 2015-08-11 2018-06-20 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US11890301B2 (en) 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3340998B1 (en) 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
AU2016344459B2 (en) 2015-10-28 2023-10-05 Yale University Humanized anti-DKK2 antibody and uses thereof
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
EP3370764A4 (en) 2015-11-05 2019-07-17 The Regents of The University of California CELLS MARKED BY LIPID CONJUGATES AND METHODS OF USING THE SAME
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
EP4335851A3 (en) 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10188660B2 (en) 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CA3006984C (en) 2015-12-15 2023-10-17 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
AU2017204683B2 (en) 2015-12-31 2023-03-16 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CN108699154A (zh) 2016-02-26 2018-10-23 国家医疗保健研究所 对btla具有特异性的抗体及其用途
NZ745263A (en) 2016-03-02 2022-07-01 Idexx Lab Inc Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US20190262327A1 (en) 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
MA43716A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels de ceux-ci
PL3219726T3 (pl) 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
KR102571700B1 (ko) 2016-03-17 2023-08-29 누맙 세러퓨틱스 아게 항TNFα 항체 및 이의 기능성 단편
DK3219727T3 (da) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
MX2018012615A (es) 2016-04-15 2019-05-30 Novartis Ag Composiciones y metodos para la expresion selectiva de proteinas.
MX2018013172A (es) 2016-04-27 2019-02-21 Abbvie Inc Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
WO2017191062A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
PT3626273T (pt) 2016-05-17 2021-03-09 Abbvie Inc Conjugados de fármacos com anticorpo anti-cmet e métodos para o seu uso
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
PT3464361T (pt) 2016-05-27 2021-12-27 Abbvie Biotherapeutics Inc Anticorpos anti-cd40 e suas utilizações
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
LT3458479T (lt) 2016-06-08 2021-02-25 Abbvie Inc. Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
AU2017297603A1 (en) 2016-07-14 2019-02-14 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
AU2017299854A1 (en) 2016-07-18 2019-01-31 Helix Biopharma Corp. CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
SG11201900677SA (en) 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
EP3491022A1 (en) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies targeting tumor associated macrophages and uses thereof
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109923129A (zh) 2016-08-26 2019-06-21 新加坡科技研究局 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途
CN109862912B (zh) 2016-08-29 2024-08-02 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
PT4050034T (pt) 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
KR102561356B1 (ko) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
UA126565C2 (uk) 2016-09-19 2022-11-02 Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. Антитіло до гм-ксф
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
JP7217970B2 (ja) 2016-10-07 2023-02-06 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いてｔ細胞受容体をリプログラミングするための組成物及び方法
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
AU2017353939A1 (en) 2016-11-07 2019-06-06 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11773163B2 (en) 2016-11-21 2023-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
SI3551660T1 (sl) 2016-12-07 2024-02-29 Agenus Inc. Protitelesa proti antictla-4 in načini njihove uporabe
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
JP6772385B2 (ja) 2016-12-15 2020-10-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｏｘ４０抗体及びそれらの使用
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
UY37544A (es) 2016-12-22 2018-07-31 Sanofi Sa Anticuerpos humanizados contra cxcr3 con actividad mermadora y métodos de uso de los mismos
JP7211952B2 (ja) 2017-01-05 2023-01-24 ネトリス ファーマ ネトリン－１干渉薬及び免疫チェックポイント阻害薬による併用治療
WO2018127791A2 (en) 2017-01-06 2018-07-12 Biosion, Inc. Erbb2 antibodies and uses therefore
CN110291109B (zh) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 人程序性死亡受体pd-1的单克隆抗体及其片段
ES2908662T3 (es) 2017-01-24 2022-05-03 I Mab Biopharma Us Ltd Anticuerpos anti-CD73 y usos de los mismos
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
CN110612309A (zh) 2017-03-27 2019-12-24 细胞基因公司 用于降低免疫原性的方法和组合物
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN110891970B (zh) 2017-04-14 2024-05-10 埃克塞里艾克西斯公司 用于预防或治疗癌症的amhrii结合化合物
BR112019021495A8 (pt) 2017-04-14 2023-05-02 Inst Curie Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres de pulmão
MA50958A (fr) 2017-04-21 2020-10-14 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
CN111194221A (zh) * 2017-05-10 2020-05-22 威斯塔解剖学和生物学研究所 优化的核酸抗体构建体
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
US12116406B2 (en) 2017-05-26 2024-10-15 Fred Hutchinson Cancer Center Anti-CD33 antibodies and uses thereof
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
CN111246867B (zh) 2017-06-01 2024-04-12 阿卡米斯生物公司 溶瘤病毒和方法
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
AU2018306436A1 (en) 2017-07-27 2020-02-13 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
CN117050176A (zh) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
WO2019046338A1 (en) 2017-08-28 2019-03-07 Angiex, Inc. ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
JP7226833B2 (ja) 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
CA3115374A1 (en) 2017-10-12 2019-04-18 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
AU2018346955B2 (en) 2017-10-13 2024-08-29 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
KR20200087176A (ko) 2017-11-14 2020-07-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
SG11202006042SA (en) 2017-12-27 2020-07-29 Teneobio Inc Cd3-delta/epsilon heterodimer specific antibodies
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
CN111727058A (zh) 2018-02-23 2020-09-29 卡瑟里克斯私人有限公司 靶向tag-72的t细胞疾病治疗
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
AU2019248547A1 (en) 2018-04-02 2020-09-10 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
JP7530638B2 (ja) 2018-05-10 2024-08-08 ニューラクル サイエンス カンパニー リミテッド 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
EA202092839A1 (ru) 2018-05-24 2021-02-12 Янссен Байотек, Инк. Агенты, связывающиеся с psma, и виды их применения
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
WO2020002592A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Traf2 inhibitors for use in the treatment of a cancer
CN112533635A (zh) 2018-07-10 2021-03-19 田边三菱制药株式会社 末梢神经病变或者伴随确认到末梢神经病变或星形胶质细胞病变的疾病的疼痛的预防或治疗方法
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US20210253666A1 (en) 2018-08-30 2021-08-19 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP4268831A3 (en) 2018-09-12 2024-05-22 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
EP3853252A1 (en) 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
MA53811A (fr) 2018-10-03 2022-03-16 Staten Biotechnology B V Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
JP2022512860A (ja) 2018-11-06 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
US20220026445A1 (en) 2018-12-07 2022-01-27 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
US20220064260A1 (en) 2018-12-14 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
US20220289857A1 (en) 2018-12-20 2022-09-15 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
AU2020218446B2 (en) 2019-02-04 2023-05-25 National University Corporation Ehime University "CAR LIBRARY AND scFv MANUFACTURING METHOD
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. CD3 ANTIGEN-BINDING FRAGMENT AND APPLICATION THEREOF
CN112142847B (zh) 2019-02-22 2023-05-05 武汉友芝友生物制药股份有限公司 改造的Fc片段，包含其的抗体及其应用
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
BR112021018611A2 (pt) 2019-03-20 2021-11-23 Imcheck Therapeutics Sas Anticorpos tendo especificidade para btn2 e usos dos mesmos
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
US20210277131A1 (en) 2019-03-26 2021-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
US20220257796A1 (en) 2019-07-02 2022-08-18 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
BR112022000416A2 (pt) 2019-07-11 2022-03-03 Wuhan Yzy Biopharma Co Ltd Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
EP4013506A1 (en) 2019-08-12 2022-06-22 Aptevo Research and Development LLC 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021043206A1 (zh) 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
US20230037414A1 (en) 2019-11-22 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
US20230227559A1 (en) 2019-12-10 2023-07-20 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
EP4091633A4 (en) 2020-01-15 2024-07-10 Univ Osaka PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST DEMENTIA
CN118697868A (zh) 2020-01-15 2024-09-27 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
CN115397848A (zh) 2020-02-05 2022-11-25 拉利玛生物医药公司 Tat肽结合蛋白及其用途
US20230192900A1 (en) 2020-02-13 2023-06-22 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
WO2021160268A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9
WO2021160267A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
WO2021160265A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
EP4103610A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
US11180563B2 (en) 2020-02-21 2021-11-23 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
TW202200209A (zh) 2020-02-28 2022-01-01 美商健臻公司 用於優化之藥物接合之經修飾的結合多肽
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
KR20220167276A (ko) 2020-03-10 2022-12-20 매사추세츠 인스티튜트 오브 테크놀로지 NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A4 (en) 2020-03-31 2024-06-26 Bio-Thera Solutions, Ltd. ANTIBODIES AND FUSION PROTEIN FOR THE TREATMENT OF CORONAVIRUS AND USE THEREOF
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
CA3180872A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
CA3181002A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
JP2023522395A (ja) 2020-04-24 2023-05-30 サノフイ 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフォックスを含有する抗腫瘍組み合わせ
MX2022013402A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri.
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
PE20230431A1 (es) 2020-04-29 2023-03-08 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
US11981932B2 (en) 2020-06-17 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
US20230272386A1 (en) 2020-07-17 2023-08-31 Mitsubishi Tanabe Pharma Corporation Agent for preventing or treating muscular disease
WO2022028608A1 (zh) 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
MX2023002330A (es) 2020-09-04 2023-03-21 Merck Patent Gmbh Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
JP2023544839A (ja) 2020-10-07 2023-10-25 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体及びその使用方法
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
US20240084014A1 (en) 2020-10-16 2024-03-14 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022089767A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
JP2023551113A (ja) 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． 二重特異性抗体及びその応用
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
US20240033358A1 (en) 2020-11-13 2024-02-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multispecific antibodies and antibody combinations
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
CN114685660A (zh) 2020-12-30 2022-07-01 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其制备方法和应用
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
AU2022207708A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US20240115721A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
MX2023009100A (es) 2021-02-03 2023-09-25 Mozart Therapeutics Inc Agentes aglutinantes y métodos para usar los mismos.
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
JP2024508157A (ja) 2021-03-04 2024-02-22 センター ナショナル デ ラ レシェルシェ サイエンティフィーク 炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
AU2022238849A1 (en) 2021-03-17 2023-08-31 Receptos Llc Methods of treating atopic dermatitis with anti il-13 antibodies
MX2023011340A (es) 2021-03-26 2023-12-14 Janssen Biotech Inc Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
WO2022235628A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
JP2024527551A (ja) 2021-06-29 2024-07-25 シージェン インコーポレイテッド 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法
KR20240095160A (ko) 2021-07-29 2024-06-25 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 인간화된 항-인간 βig-h3 단백질 및 이의 용도
EP4377335A1 (en) 2021-07-29 2024-06-05 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3227511A1 (en) 2021-08-06 2023-02-09 Lætitia LINARES Methods for the treatment of cancer
AU2022325950A1 (en) 2021-08-11 2024-02-22 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｌａｍｐ１抗体およびその使用
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4410839A1 (en) 2021-09-30 2024-08-07 Bio-Thera Solutions, Ltd. Anti-b7-h3 antibody and application thereof
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
IL312519A (en) 2021-11-05 2024-07-01 Lilly Co Eli Anticancer combinations containing antibody-drug conjugates anti-CEACAM5 and anti-VEGFR-2 antibodies
EP4436998A1 (en) 2021-11-24 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023116911A1 (zh) 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
TW202337904A (zh) 2022-01-07 2023-10-01 美商壯生和壯生企業創新公司 ＩＬ－１β結合蛋白之材料及方法
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
WO2023170239A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Methods and tools for conjugation to antibodies
AU2023230951A1 (en) 2022-03-09 2024-09-05 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
TW202400636A (zh) 2022-03-11 2024-01-01 比利時商健生藥品公司 多特異性抗體及其用途(一)
WO2023170295A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024115393A1 (en) 2022-11-28 2024-06-06 UCB Biopharma SRL Treatment of fibromyalgia
GB202217923D0 (en) 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
WO2024138144A1 (en) * 2022-12-22 2024-06-27 The Medical College Of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
GB202301949D0 (en) 2023-02-10 2023-03-29 Coding Bio Ltd CLL1 and/or CD33 binding molecules
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
WO2024180192A1 (en) 2023-03-01 2024-09-06 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194455A1 (en) 2023-03-23 2024-09-26 Sanofi CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract
WO2024209089A1 (en) 2023-04-07 2024-10-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
AU618989B2 (en) * 1988-02-12 1992-01-16 British Technology Group Limited Improvements in or relating to antibodies
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) * 1989-12-18 1991-11-05 Oronzio Denora S.A. Method and apparatus for cathodic protection
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
JPH06202412A (ja) * 1992-12-26 1994-07-22 Canon Inc 画像形成装置
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5535089A (en) * 1994-10-17 1996-07-09 Jing Mei Industrial Holdings, Ltd. Ionizer

Also Published As

Publication number Publication date
US20040202662A1 (en) 2004-10-14
NO316074B1 (no) 2003-12-08
US20050123534A1 (en) 2005-06-09
US20050136054A1 (en) 2005-06-23
ATE159299T1 (de) 1997-11-15
AU631481B2 (en) 1992-11-26
AU7048691A (en) 1991-07-24
US7244615B2 (en) 2007-07-17
NO985468L (no) 1991-10-21
RO114232B1 (ro) 1999-02-26
NO985468D0 (no) 1998-11-23
AU6974091A (en) 1991-07-24
AU649645B2 (en) 1994-06-02
HU217693B (hu) 2000-03-28
US20040071693A1 (en) 2004-04-15
ES2165864T3 (es) 2002-04-01
DK0460171T3 (da) 1995-08-28
EP0460178B1 (en) 1997-10-15
ATE208794T1 (de) 2001-11-15
DK0626390T3 (da) 2002-03-11
ES2074701T3 (es) 1995-09-16
NO913228D0 (no) 1991-08-19
KR100198478B1 (en) 1999-06-15
DE69031591D1 (de) 1997-11-20
DE69022982T2 (de) 1996-03-28
DE69020544D1 (de) 1995-08-03
EP0460178A1 (en) 1991-12-11
EP0460171B1 (en) 1995-06-28
GB9117611D0 (en) 1991-10-02
KR100197956B1 (ko) 1999-06-15
ATE129017T1 (de) 1995-10-15
GB8928874D0 (en) 1990-02-28
WO1991009967A1 (en) 1991-07-11
US20060073136A1 (en) 2006-04-06
CA2050479C (en) 1997-03-25
NO913229D0 (no) 1991-08-19
GB2246781B (en) 1994-05-11
NO913271D0 (no) 1991-08-20
EP0626390A1 (en) 1994-11-30
HU215383B (hu) 2000-03-28
DE69031591T2 (de) 1998-03-12
EP0460167B1 (en) 1995-10-11
BG95018A (bg) 1993-12-24
JP3242913B2 (ja) 2001-12-25
CA2046904A1 (en) 1991-06-22
DK0460178T3 (da) 1997-12-22
DE69033857T2 (de) 2002-09-12
NO913228L (no) 1991-10-21
FI913926A0 (fi) 1991-08-20
FI913932A0 (fi) 1991-08-20
GB2246570B (en) 1994-05-11
NO316076B1 (no) 2003-12-08
AU646009B2 (en) 1994-02-03
FI109768B (sv) 2002-10-15
US7244832B2 (en) 2007-07-17
BG60462B1 (bg) 1995-04-28
US5929212A (en) 1999-07-27
DK0460167T3 (da) 1995-11-20
CA2037607A1 (en) 1992-09-07
ZA9110129B (en) 1993-06-23
KR100191152B1 (ko) 1999-06-15
ES2112270T3 (es) 1998-04-01
JPH04505398A (ja) 1992-09-24
FI108917B (sv) 2002-04-30
KR920701465A (ko) 1992-08-11
GB2268744A (en) 1994-01-19
EP0460171A1 (en) 1991-12-11
HUT58824A (en) 1992-03-30
GB9318911D0 (en) 1993-10-27
NO310560B1 (no) 2001-07-23
WO1991009966A1 (en) 1991-07-11
AU664801B2 (en) 1995-11-30
GB9117612D0 (en) 1991-11-20
GB2246781A (en) 1992-02-12
US7241877B2 (en) 2007-07-10
NO985467L (no) 1991-10-21
WO1991009968A1 (en) 1991-07-11
GR3025781T3 (en) 1998-03-31
HU912751D0 (en) 1992-01-28
US20060073137A1 (en) 2006-04-06
GR3017734T3 (en) 1996-01-31
EP0460167A1 (en) 1991-12-11
DE69022982D1 (de) 1995-11-16
HUT58372A (en) 1992-02-28
US20040076627A1 (en) 2004-04-22
JP3452062B2 (ja) 2003-09-29
FI990875A0 (sv) 1999-04-19
RO114980B1 (ro) 1999-09-30
JPH11243955A (ja) 1999-09-14
BR9007197A (pt) 1992-01-28
CA2050479A1 (en) 1991-06-22
NO913229L (no) 1991-10-21
AU7033091A (en) 1991-07-24
NO985467D0 (no) 1998-11-23
ATE124459T1 (de) 1995-07-15
FI913927A0 (fi) 1991-08-20
US20050202529A1 (en) 2005-09-15
FI990875A (sv) 1999-04-19
JPH04506458A (ja) 1992-11-12
US7262050B2 (en) 2007-08-28
NO913271L (no) 1991-08-20
RU2112037C1 (ru) 1998-05-27
CA2046904C (en) 2003-12-02
HUT60786A (en) 1992-10-28
FI108776B (sv) 2002-03-28
GB2246570A (en) 1992-02-05
DE69020544T2 (de) 1996-01-18
EP0620276A1 (en) 1994-10-19
HU912752D0 (en) 1992-01-28
CA2037607C (en) 2005-05-24
US20060029593A1 (en) 2006-02-09
DE69033857D1 (de) 2001-12-20
EP0626390B1 (en) 2001-11-14
JPH05500312A (ja) 1993-01-28
AU6461294A (en) 1994-12-22
ES2079638T3 (es) 1996-01-16
RO114298B1 (ro) 1999-03-30
GB2268744B (en) 1994-05-11

Similar Documents

Publication Publication Date Title
FI108777B (sv) Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft
USRE48787E1 (en) Humanised antibodies
US6750325B1 (en) CD3 specific recombinant antibody
USRE50178E1 (en) Humanised antibodies
Poul et al. Inhibition of T cell activation with a humanized anti-β1 integrin chain mAb
CA2129219C (en) Humanised antibodies
GB2268745A (en) Humanised antibodies.
LEFRANC INHIBITION OF T CELL ACTIVATION WITH A HUMANIZED ANTI-/31 INTEGRIN CHAIN mAb